-
Company Insights
Innovation and Patenting activity of TCR2 Therapeutics Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of TCR2 Therapeutics Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – ONCT-808 in Follicular Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ONCT-808 in Follicular Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ONCT-808 in Follicular Lymphoma Drug Details: ONCT-808 is under development for the treatment...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Rilzabrutinib in Asthma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rilzabrutinib in Asthma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rilzabrutinib in Asthma Drug Details: Rilzabrutinib (PRN-1008) is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cadonilimab in Hepatocellular Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cadonilimab in Hepatocellular Carcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cadonilimab in Hepatocellular Carcinoma Drug Details: Cardinalizumab (Ketanil) is a bi-specific...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AGI-134 in Synovial Sarcoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. AGI-134 in Synovial Sarcoma Drug Details: AGI-134 is under development for the treatment of solid...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – TC-110 in Mantle Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TC-110 in Mantle Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TC-110 in Mantle Cell Lymphoma Drug Details: TC-110 is under development...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – TC-110 in Follicular Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TC-110 in Follicular Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TC-110 in Follicular Lymphoma Drug Details: TC-110 is under development for the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – TC-110 in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TC-110 in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TC-110 in Acute Lymphocytic Leukemia (ALL, Acute...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Azacitidine in Relapsed Acute Myeloid Leukemia
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Azacitidine in Relapsed Acute Myeloid Leukemia Drug Details: Azacitidine (Vidaza, Azafuridine, Celazadine) is a pyrimidine...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Atezolizumab in Uterine Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Atezolizumab in Uterine Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Atezolizumab in Uterine Cancer Drug Details: Atezolizumab (Tecentriq) is an antineoplastic...